Bloodstream Infections by Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Children: Epidemiology and Clinical Outcome
Open Access
- 1 May 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (5) , 1481-1491
- https://doi.org/10.1128/aac.46.5.1481-1491.2002
Abstract
To determine the epidemiologic features and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, cases of bacteremia caused by these organisms in children were analyzed retrospectively. Among the 157 blood isolates recovered from 1993 to 1998 at the Seoul National University Children's Hospital, the prevalence of ESBL production was 17.9% among the E. coli isolates and 52.9% among the K. pneumoniae isolates. The commonest ESBLs were SHV-2a and TEM-52. A novel ESBL, TEM-88, was identified. Pulsed-field gel electrophoresis analysis of the ESBL-producing organisms showed extensive diversity in clonality. The medical records of 142 episodes were reviewed. The risk factors for bloodstream infection with ESBL-producing organisms were prior hospitalization, prior use of oxyimino-cephalosporins, and admission to an intensive care unit within the previous month. There was no difference in clinical severity between patients infected with ESBL-producing strains (the ESBL group) and those infected with ESBL-nonproducing strains (the non-ESBL group) at the time of presentation. However, the overall fatality rate for the ESBL group was significantly higher than that for the non-ESBL group: 12 of 45 (26.7%) versus 5 of 87 (5.7%) ( P = 0.001). In a subset analysis of patients treated with extended-spectrum cephalosporins with or without an aminoglycoside, favorable response rates were significantly higher in the non-ESBL group at the 3rd day (6 of 17 versus 33 of 51; P = 0.035), the 5th day (6 of 17 versus 36 of 50; P < 0.05), and the end of therapy (9 of 17 versus 47 of 50; P < 0.001). In conclusion, the ESBL production of the infecting organisms has a significant impact on the clinical course and survival of pediatric patients with bacteremia caused by E. coli and K. pneumoniae .Keywords
This publication has 31 references indexed in Scilit:
- Evolution of TEM-Related Extended-Spectrum β-Lactamases in KoreaAntimicrobial Agents and Chemotherapy, 2001
- Identification of CTX-M-14 Extended-Spectrum β-Lactamase in Clinical Isolates of Shigella sonnei , Escherichia coli , and Klebsiella pneumoniae in KoreaJournal of Clinical Microbiology, 2001
- Trends in β‐Lactam Resistance Among EnterobacteriaceaeClinical Infectious Diseases, 1998
- Nomenclature of TEM beta-lactamasesJournal of Antimicrobial Chemotherapy, 1997
- Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Bloodstream Infection: A Case-Control and Molecular Epidemiologic InvestigationThe Journal of Infectious Diseases, 1996
- Molecular Genetics of Resistance to Both Ceftazidime and β-Lactam-β-Lactamase Inhibitor Combinations in Klebsiella pneumoniae and In Vivo Response to β-Lactam TherapyThe Journal of Infectious Diseases, 1996
- Enterococcus faecium and Enterococcus faecalis Bacteremia: Acquisition and OutcomeClinical Infectious Diseases, 1995
- Extended-spectrum β-Iactamases in Escherichia coli and Klebsiella spp. in European septicaemia isolatesJournal of Antimicrobial Chemotherapy, 1993
- ss-Lactam Antibiotic-Induced Release of Free Endotoxin: In Vitro Comparison of Penicillin-Binding Protein (PBP) 2-Specific Imipenem and PBP 3-Specific CeftazidimeThe Journal of Infectious Diseases, 1992
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975